Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 19 December 2025 - 24 December 2025

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences Ltd. (NASDAQ: WVE) is ending 2025 as one of biotech’s most watched “story stocks”—the kind that can go from sleepy to screaming in a single premarket headline, then spend weeks digesting what just happened. On December 24, 2025, Wave shares traded in the high teens (around ~$18), still hovering near the re-rated levels that followed its early obesity readout and a sizable capital raise earlier this month. Multiple market data sources showed WVE around $18.1–$18.5 intraday, with the day’s range roughly $17.49 to ~$18.5. StockAnalysis+2Investing.com Australia+2 Below is a consolidated, publication-ready look at the most relevant WVE
24 December 2025
·
Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Dec. 24, 2025 — Regencell Bioscience Holdings Limited (NASDAQ: RGC) is having one of those “stock market is a strange animal” moments again: the share price is moving sharply on a story dominated less by traditional fundamentals and more by market structure—low float, extreme volatility, and ongoing legal overhang. As of Dec. 24, 2025, RGC was trading around $25.25, up roughly 14% on the day. Below is a complete, publication-ready roundup of what’s new today (12/24/2025), what the most current forecasts/models are implying, and what the latest filings and third‑party analysis say about the risks that keep following this stock
24 December 2025
··
Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question

Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question

Indaptus Therapeutics, Inc. (NASDAQ: INDP) is getting unusual attention heading into December 24, 2025, after a late-December SEC filing laid out a $6.0 million preferred-stock financing, a boardroom reshuffle, and a new co-CEO / chairman appointment—a mix that can ignite short-term trading interest while also forcing investors to re-run the long-term share-count math. SEC+1 The key tension is straightforward: the deal injects capital into a clinical-stage biotech that has been funding itself through repeated capital raises, but it also introduces a preferred security that—if shareholders approve conversion—could translate into up to 111 million common shares. In micro-cap land, that number
24 December 2025
··
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

December 24, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending 2025 with the kind of chart action that makes both traders and long-term biotech investors sit up straight. After a sharp multi-day run, Moderna stock pulled back hard: shares closed at about $32.29 on Dec. 23, down ~7.48% on the day, and were indicated around $32.11 in pre-market trading on Dec. 24. StockAnalysis That drop matters—but so does the context. The pullback follows a late-December surge that coincided with multiple headlines touching Moderna’s near-term product story (respiratory vaccines), its longer-term optionality (oncology and next-gen platforms), and its financial runway (new
24 December 2025
··
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics Inc. (NASDAQ: GPCR) is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven by blockbuster obesity-trial headlines, a major equity financing, and a wave of analyst price-target updates. Below is a comprehensive roundup of the latest news, forecasts, and analysis available as of 23.12.2025, and what investors are watching next. What is Structure Therapeutics, and why does GPCR trade like a headline detector? Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule
23 December 2025
····
Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

Amgen Inc. (NASDAQ: AMGN) ended Monday, December 22, 2025, modestly higher, but the more important story for Tuesday’s open is what hit after the closing bell: fresh FDA approvals for new denosumab biosimilars that reference Amgen’s blockbuster bone-drug franchises Prolia and XGEVA—plus a credit-rating upgrade from Fitch that underscores improving balance-sheet flexibility. Below is a complete, investor-focused rundown of what moved (and what could move) Amgen stock before the U.S. market opens Tuesday, December 23, 2025. AMGN stock recap: where Amgen closed and what after-hours traders saw Amgen shares finished the regular session at $331.39, up about 1.2% on the
23 December 2025
···
Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience Corporation (NASDAQ: TWST) is ending 2025 with something investors in “tools + genomics” names haven’t always been able to count on: momentum that’s tied to multiple moving pieces—new product launches, partner-driven workflow wins, and a profitability narrative that’s finally getting sharper edges. On December 22, 2025, TWST shares were trading around $34.26, up about 5.4% on the session at the time of writing (midday U.S. trading). MarketScreener That pop isn’t happening in a vacuum. Over the past few weeks, the company has stacked up incremental catalysts—from a fresh licensing deal touching NGS and hot-start PCR, to product expansion
22 December 2025
··
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology stocks head into the Christmas-shortened trading week with fresh momentum—and plenty for investors to digest—after a dense run of catalysts between December 19 and December 21, 2025. In the span of 48 hours, the sector saw a major rare-disease acquisition, a closely watched FDA approval in cardiology, IPO paperwork from both biotech and medtech, and a sweeping wave of U.S. drug-pricing headlines that could reshape sentiment into 2026. Investopedia+4Reuters+4Reuters+4 The setup matters because next week’s market structure will be unusual: U.S. stock markets are scheduled to close early on Wednesday, December 24 (1:00 p.m. ET) and remain closed on
21 December 2025
·····
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight heading into December 20, 2025—not because of a single blockbuster headline, but because the stock just posted a sharp, high-volume move that traders and long-term biotech investors both tend to notice. With Edgewise still a clinical-stage company, the share price often reflects a shifting mix of (1) expectations for clinical readouts, (2) perceived regulatory timelines, and (3) sentiment in the biotech tape. In other words: EWTX can move fast—even when the company itself hasn’t issued fresh news in the last 24–48 hours. Below is a comprehensive look at the latest
21 December 2025
··
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50 per share sparked a sharp re-pricing of Amicus shares, which have been hovering just below the bid as investors weigh deal timing, closing risk, and what the buyout means for Amicus’ two commercial rare-disease franchises—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease). SEC+1 Below is a detailed breakdown of the latest news (as of 20.12.2025), plus the most relevant
20 December 2025
·····
Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO) is back in the spotlight on Friday, December 19, 2025, as investors weigh a fresh set of operational updates, capital-return signals, and Wall Street forecasts. Shares were trading around $569.54, up about 1.27% on the day, giving the life sciences and diagnostics giant a market value near $218 billion. While Thermo Fisher is often viewed as a “pick-and-shovel” leader powering biotech, pharma and academic research, the stock story right now is about something more specific: how well the company can convert a rebound in U.S. biopharma activity into durable growth—while navigating China pressure, government
19 December 2025
··
Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

December 19, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight after a sharp one-day rebound that followed a volatile stretch for the clinical-stage biotech. EWTX closed Dec. 19, 2025 at $23.01, up +8.79% on the day after trading between roughly $21.49 and $23.84 on elevated activity. Investing.com For investors, today’s price action is the “symptom.” The bigger story is the “disease biology”: Edgewise is building a pipeline aimed at muscular dystrophies and serious cardiac conditions, with multiple clinical readouts and program updates spaced across late 2025 and beyond. PR Newswire+1 Below is what’s moving the narrative
19 December 2025
··
1 … 9 10 11 12 13 … 25

Stock Market Today

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
Washington, Feb 7, 2026, 07:38 (EST) The IRS has not announced any new federal stimulus payments for February 2026, and Congress has not authorized another round of checks, Fox 5 DC reported. Online posts pushing $2,000 “tariff dividend” checks or other direct deposits have continued into 2026, sometimes mixing in state programs such as Alaska’s Permanent Fund Dividend, the report said. (fox5dc.com) The timing matters because tax filing season tends to put millions of people in “money-watching” mode. Refunds, credits and routine deposits hit bank accounts, and scammers try to ride the noise. President Donald Trump’s own comments have added
Go toTop